In this webinar, we will discuss the development of a new, noninvasive method for Alzheimer’s disease (AD) diagnostics based on Raman spectroscopy of blood
When cleared, Fujirebio’s FDA-designated breakthrough device is expected to be among the first commercially available in vitro diagnostics for patients being evaluated for Alzheimer’s disease in the US